Yosuke Ishii1,2, Thoralf Thamm1,3, Jia Guo1,4, Mohammad Mehdi Khalighi5, Mirwais Wardak1, Dawn Holley1, Harsh Gandhi1, Jun Hyung Park1, Bin Shen1, Gary K Steinberg6, Frederick T Chin1, Greg Zaharchuk1, Audrey Peiwen Fan1. 1. Department of Radiology, Stanford University, Stanford, California, USA. 2. Department of Neurosurgery, Tokyo Medical and Dental University, Tokyo, Japan. 3. Center for Stroke Research Berlin (CSB), Charité - Universitätsmedizin Berlin, Berlin, Germany. 4. Department of Bioengineering, University of California Riverside, Riverside, California, USA. 5. Global Applied Science Lab, GE Healthcare, Menlo Park, California, USA. 6. Department of Neurosurgery, Stanford University, Stanford, California, USA.
Abstract
BACKGROUND: H2 15 O-positron emission tomography (PET) is considered the reference standard for absolute cerebral blood flow (CBF). However, this technique requires an arterial input function measured through continuous sampling of arterial blood, which is invasive and has limitations with tracer delay and dispersion. PURPOSE: To demonstrate a new noninvasive method to quantify absolute CBF with a PET/MRI hybrid scanner. This blood-free approach, called PC-PET, takes the spatial CBF distribution from a static H2 15 O-PET scan, and scales it to the whole-brain average CBF value measured by simultaneous phase-contrast MRI. STUDY TYPE: Observational. SUBJECTS: Twelve healthy controls (HC) and 13 patients with Moyamoya disease (MM) as a model of chronic ischemic disease. FIELD STRENGTH/SEQUENCES: 3T/2D cardiac-gated phase-contrast MRI and H2 15 O-PET. ASSESSMENT: PC-PET CBF values from whole brain (WB), gray matter (GM), and white matter (WM) in HCs were compared with literature values since 2000. CBF and cerebrovascular reactivity (CVR), which is defined as the percent CBF change between baseline and post-acetazolamide (vasodilator) scans, were measured by PC-PET in MM patients and HCs within cortical regions corresponding to major vascular territories. Statistical Tests: Linear, mixed effects models were created to compare CBF and CVR, respectively, between patients and controls, and between different degrees of stenosis. RESULTS: The mean CBF values in WB, GM, and WM in HC were 42 ± 7 ml/100 g/min, 50 ± 7 ml/100 g/min, and 23 ± 3 ml/100 g/min, respectively, which agree well with literature values. Compared with normal regions (57 ± 23%), patients showed significantly decreased CVR in areas with mild/moderate stenosis (47 ± 17%, P = 0.011) and in severe/occluded areas (40 ± 16%, P = 0.016). Data Conclusion: PC-PET identifies differences in cerebrovascular reactivity between healthy controls and cerebrovascular patients. PC-PET is suitable for CBF measurement when arterial blood sampling is not accessible, and warrants comparison to fully quantitative H2 15 O-PET in future studies. LEVEL OF EVIDENCE: 3 Technical Efficacy Stage: 2 J. Magn. Reson. Imaging 2019. J. Magn. Reson. Imaging 2020;51:183-194.
BACKGROUND:H2 15 O-positron emission tomography (PET) is considered the reference standard for absolute cerebral blood flow (CBF). However, this technique requires an arterial input function measured through continuous sampling of arterial blood, which is invasive and has limitations with tracer delay and dispersion. PURPOSE: To demonstrate a new noninvasive method to quantify absolute CBF with a PET/MRI hybrid scanner. This blood-free approach, called PC-PET, takes the spatial CBF distribution from a static H2 15 O-PET scan, and scales it to the whole-brain average CBF value measured by simultaneous phase-contrast MRI. STUDY TYPE: Observational. SUBJECTS: Twelve healthy controls (HC) and 13 patients with Moyamoya disease (MM) as a model of chronic ischemic disease. FIELD STRENGTH/SEQUENCES: 3T/2D cardiac-gated phase-contrast MRI and H2 15 O-PET. ASSESSMENT: PC-PET CBF values from whole brain (WB), gray matter (GM), and white matter (WM) in HCs were compared with literature values since 2000. CBF and cerebrovascular reactivity (CVR), which is defined as the percent CBF change between baseline and post-acetazolamide (vasodilator) scans, were measured by PC-PET in MM patients and HCs within cortical regions corresponding to major vascular territories. Statistical Tests: Linear, mixed effects models were created to compare CBF and CVR, respectively, between patients and controls, and between different degrees of stenosis. RESULTS: The mean CBF values in WB, GM, and WM in HC were 42 ± 7 ml/100 g/min, 50 ± 7 ml/100 g/min, and 23 ± 3 ml/100 g/min, respectively, which agree well with literature values. Compared with normal regions (57 ± 23%), patients showed significantly decreased CVR in areas with mild/moderate stenosis (47 ± 17%, P = 0.011) and in severe/occluded areas (40 ± 16%, P = 0.016). Data Conclusion: PC-PET identifies differences in cerebrovascular reactivity between healthy controls and cerebrovascular patients. PC-PET is suitable for CBF measurement when arterial blood sampling is not accessible, and warrants comparison to fully quantitative H2 15 O-PET in future studies. LEVEL OF EVIDENCE: 3 Technical Efficacy Stage: 2 J. Magn. Reson. Imaging 2019. J. Magn. Reson. Imaging 2020;51:183-194.
Authors: O Togao; F Mihara; T Yoshiura; A Tanaka; T Noguchi; Y Kuwabara; K Kaneko; T Matsushima; H Honda Journal: AJNR Am J Neuroradiol Date: 2006-02 Impact factor: 3.825
Authors: Greg Zaharchuk; Huy M Do; Michael P Marks; Jarrett Rosenberg; Michael E Moseley; Gary K Steinberg Journal: Stroke Date: 2011-07-28 Impact factor: 7.914
Authors: F Q Ye; K F Berman; T Ellmore; G Esposito; J D van Horn; Y Yang; J Duyn; A M Smith; J A Frank; D R Weinberger; A C McLaughlin Journal: Magn Reson Med Date: 2000-09 Impact factor: 4.668
Authors: Ke Zhang; Hans Herzog; Jörg Mauler; Christian Filss; Thomas W Okell; Elena Rota Kops; Lutz Tellmann; Thomas Fischer; Burkhard Brocke; Walter Sturm; Heinz H Coenen; N Jon Shah Journal: J Cereb Blood Flow Metab Date: 2014-05-21 Impact factor: 6.200
Authors: Mark Bitsch Vestergaard; Ulrich Lindberg; Niels Jacob Aachmann-Andersen; Kristian Lisbjerg; Søren Just Christensen; Peter Rasmussen; Niels Vidiendal Olsen; Ian Law; Henrik Bo Wiberg Larsson; Otto Mølby Henriksen Journal: J Magn Reson Imaging Date: 2016-09-13 Impact factor: 4.813
Authors: David Y T Chen; Yosuke Ishii; Audrey P Fan; Jia Guo; Moss Y Zhao; Gary K Steinberg; Greg Zaharchuk Journal: Radiology Date: 2020-07-14 Impact factor: 11.105
Authors: Moss Y Zhao; Audrey P Fan; David Yen-Ting Chen; Yosuke Ishii; Mohammad Mehdi Khalighi; Michael Moseley; Gary K Steinberg; Greg Zaharchuk Journal: J Cereb Blood Flow Metab Date: 2022-03-02 Impact factor: 6.960
Authors: Moss Y Zhao; Audrey P Fan; David Yen-Ting Chen; Magdalena J Sokolska; Jia Guo; Yosuke Ishii; David D Shin; Mohammad Mehdi Khalighi; Dawn Holley; Kim Halbert; Andrea Otte; Brittney Williams; Taghi Rostami; Jun-Hyung Park; Bin Shen; Greg Zaharchuk Journal: Neuroimage Date: 2021-03-11 Impact factor: 6.556
Authors: Lucas Narciso; Tracy Ssali; Linshan Liu; Heather Biernaski; John Butler; Laura Morrison; Jennifer Hadway; Jeffrey Corsaut; Justin W Hicks; Michael C Langham; Felix W Wehrli; Hidehiro Iida; Keith St Lawrence Journal: J Nucl Med Date: 2021-03-19 Impact factor: 11.082
Authors: Shengwen Deng; Crystal G Franklin; Michael O'Boyle; Wei Zhang; Betty L Heyl; Paul A Jerabek; Hanzhang Lu; Peter T Fox Journal: Neuroimage Date: 2022-01-20 Impact factor: 7.400
Authors: Markus Fahlström; Lieuwe Appel; Eva Kumlien; Torsten Danfors; Mathias Engström; Johan Wikström; Gunnar Antoni; Elna-Marie Larsson; Mark Lubberink Journal: Diagnostics (Basel) Date: 2021-05-01